

CANCER DISCOVERY 5 JAN-MAR 2015 1-3

RC 261  
.A1  
C3747  
Set 1

# CANCER DISCOVERY

JANUARY 2015 ■ VOLUME 5 ■ NUMBER 1

Cancer discovery (Print)

RC261 .A1 C3747 v. 5, no. 1 (2015 Jan.)

uf30

2011-204352



c-Ser

2013 IMPACT FACTOR  
**15.929**

[www.aacrjournals.org](http://www.aacrjournals.org)

**AACR**

American Association for Cancer Research

## EDITORS-IN-CHIEF

Lewis C. Cantley      José Baselga

## EXECUTIVE EDITORS

Mark W. Landis      Judy N. Quong

## SCIENTIFIC EDITORS

Kari Alitalo  
James P. Allison  
Scott A. Armstrong  
Carlos L. Arteaga  
Alan Ashworth  
René Bernards  
Elizabeth H. Blackburn  
Paolo Boffetta  
Joan S. Brugge  
John C. Byrd  
Andrea Califano  
Arul Chinnaiyan  
Sara A. Courtneidge  
Alan D. D'Andrea  
Johann S. de Bono  
Hugues de Thé  
Ralph J. DeBerardinis  
Ronald A. DePinho  
Vishva M. Dixit  
Matthew J. Ellis  
Jeffrey A. Engelman  
Douglas T. Fearon  
Keith T. Flaherty  
Lori Friedman  
Levi A. Garraway  
Jennifer R. Grandis

Nathanael S. Gray  
Daniel A. Haber  
William C. Hahn  
Douglas Hanahan  
Manuel Hidalgo  
Waun Ki Hong  
Tyler Jacks  
William G. Kaelin  
Theodore S. Lawrence  
John P. Leonard  
Arnold J. Levine  
Douglas R. Lowy  
Tak W. Mak  
Richard M. Marais  
Joan Massagué  
Frank McCormick  
Ari M. Melnick  
Matthew L. Meyerson  
Gordon B. Mills  
Paul S. Mischel  
Sean J. Morrison  
Benjamin G. Neel  
Olufunmilayo I. Olopade  
Pier Paolo Pandolfi  
William Pao  
David R. Piwnica-Worms

Helen M. Piwnica-Worms  
Kornelia Polyak  
Carol Prives  
Antoni Ribas  
Andrea L. Richardson  
Jeffrey M. Rosen  
Mark A. Rubin  
Charles L. Sawyers  
David Schenkein  
Alice T. Shaw  
Margaret A. Shipp  
Kevan M. Shokat  
M. Celeste Simon  
Lillian L. Siu  
David B. Solit  
Laura Soucek  
Margaret R. Spitz  
Josep Tabernero  
Craig B. Thompson  
David A. Tuveson  
Victor E. Velculescu  
Robert H. Vonderheide  
Karen H. Vousden  
Xiaodong Wang  
Ralph Weissleder  
Eileen White

**Editorial Office:** Cancer Discovery [ISSN 2159-8274 (Print); ISSN 2159-8290 (Online)] is published monthly, one volume per year, by the American Association for Cancer Research, Inc., 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404. Periodicals postage is pending at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to Cancer Discovery, AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404 or E-mail: membership@aacr.org. Copyright 2015 by the American Association for Cancer Research, Inc. Printed on acid-free paper in the U.S.A.

**IN THIS ISSUE** Highlighted research articles ..... 1

**NEWS IN BRIEF** Important news stories affecting the community ..... 4

**NEWS IN DEPTH** Cancer-Killing CAR Therapies Gain Speed ..... 7

In Search of Exceptional Responders ..... 8

**RESEARCH WATCH** Selected highlights of recent articles of exceptional significance from the cancer literature ..... 9

**ONLINE** For more News and Research Watch, visit *Cancer Discovery* online at <http://CDnews.aacrjournals.org>.

### VIEWS In The Spotlight

Addressing the Controversy: Do Bisphosphonates Directly Affect Primary Tumors? ..... 14

J.A. Sterling

See article, p. 35

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy ..... 16

Y. Xiao and G.J. Freeman

See article, p. 43

Turning Telomerase into a Jekyll and Hyde Case? ..... 19

R.J. Wellinger

See article, p. 82

### In Focus

How Does Multistep Tumorigenesis Really Proceed? ..... 22

C.L. Chaffer and R.A. Weinberg

**MINI REVIEW** TRKing Down an Old Oncogene in a New Era of Targeted Therapy ..... 25

A. Vaishnavi, A.T. Le, and R.C. Doebele

**RESEARCH BRIEFS** Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskelatal Target of Bisphosphonate Action in Cancer ..... 35

S. Junankar, G. Shay, J. Jurczyk, N. Ali, J. Down, N. Pocock, A. Parker, A. Nguyen, S. Sun, B. Kashemirov, C.E. McKenna, P.I. Croucher, A. Swarbrick, K. Weilbaecher, T.G. Phan, and M.J. Rogers

**Précis:** Bisphosphonates bind granular microcalcifications and are internalized by tumor-associated macrophages in breast tumors.

See commentary, p. 14

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints ..... 43

N.J. Llosa, M. Cruise, A. Tam, E.C. Wicks, E.M. Hechenbleikner, J.M. Taube, R.L. Blosser, H. Fan, H. Wang, B.S. Lubber, M. Zhang, N. Papadopoulos, K.W. Kinzler, B. Vogelstein, C.L. Sears, R.A. Anders, D.M. Pardoll, and F. Housseau

**Précis:** Mismatch repair-deficient colorectal cancers counteract Th1/CTL immune responses by upregulating immune checkpoint proteins, including PD-1 and PD-L1.

See commentary, p. 16

Mutant KRAS-Induced Expression of ICAM-1 in Pancreatic Acinar Cells Causes Attraction of Macrophages to Expedite the Formation of Precancerous Lesions ..... 52



G.-Y. Liou, H. Döppler, B. Necela, B. Edenfield, L. Zhang, D.W. Dawson, and P. Storz

**Précis:** Crosstalk between pancreatic acinar cells and proinflammatory macrophages promotes initiation of acinar-to-ductal metaplasia via KRAS<sup>G12D</sup>-induced expression of the macrophage chemoattractant ICAM1.



**Prospective Blinded Study of  $BRAF^{V600E}$  Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders . . . . . 64**

D.M. Hyman, E.L. Diamond, C.R.T. Vibat, L. Hassaine, J.C. Poole, M. Patel, V.R. Holley, G. Cabrilo, T.T. Lu, M.E. Arcila, Y.R. Chung, R. Rampal, M.E. Lacouture, N. Rosen, F. Meric-Bernstam, J. Baselga, R. Kurzrock, M.G. Erlander, F. Janku, and O. Abdel-Wahab

**Précis:** Cell-free DNA testing using plasma and urine samples may be a reliable, noninvasive method to identify mutations and monitor treatment response in histiocytic disorders.

**Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2'-Deoxyguanosine . . . . 82**



I. Mender, S. Gryaznov, Z.G. Dikmen, W.E. Wright, and J.W. Shay

**Précis:** 6-thio-2'-deoxyguanosine is a precursor of a telomerase substrate that is incorporated into newly synthesized telomeres, leading to telomere dysfunction and death in telomerase-expressing cells.

*See commentary, p. 19*

**RESEARCH ARTICLES**

**Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer . . . 72**

M. van Kruchten, E.G. de Vries, A.W. Glaudemans, M.C. van Lanschot, M. van Faassen, I.P. Kema, M. Brown, C.P. Schröder, E.F. de Vries, and G.A. Hospers

**Précis:** Decreased [ $^{18}F$ ]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.




AC icon indicates Author Choice

For more information please visit <http://www.aacrjournals.org>

**ON THE COVER**

Hyman, Diamond, and colleagues carried out a prospective, blinded study to quantitatively detect the  $BRAF^{V600E}$  mutation in circulating tumor cell-free DNA (cfDNA) from the urine and plasma of patients with Langerhans cell histiocytosis or Erdheim-Chester disease. Urinary cfDNA analysis defined the  $BRAF$  genotype of all 30 patients and was 100% concordant with tissue genotypes among treatment-naïve patients. Furthermore, serial urinary cfDNA analyses in patients treated with a  $BRAF$  inhibitor or immunomodulatory therapy showed a progressive decrease in  $BRAF^{V600E}$  allele burden, consistent with radiographic evidence of disease improvement. Tissue and cfDNA genotyping also identified a previously unreported somatic  $KRAS^{G12S}$  mutation in a  $BRAF$  wild-type patient. These data suggest cfDNA testing as a reliable, noninvasive method to detect  $BRAF^{V600E}$  mutations and monitor response to therapy in histiocytic disorders. For details, please see the article by Hyman, Diamond, and colleagues on page 64.



### AACR OFFICERS

Carlos L. Arteaga, President  
José Baselga, President-Elect  
Charles L. Sawyers, Past President  
William N. Hait, Treasurer  
Margaret Foti, Chief Executive Officer

### PUBLICATIONS COMMITTEE

Michael E. Berens  
Gideon E. Bollag  
Michael A. Caligiuri, Chairperson  
Joseph F. Costello  
John D. Groopman  
Balveen Kaur  
Emma M. Lees  
Richard M. Marais  
William G. Nelson  
David R. Parkinson  
Elizabeth A. Repasky  
Victoria L. Seewaldt  
Catherine J. Wu

### PUBLISHING STAFF

#### Publisher

Christine B. Rullo

#### Director, Editorial Operations

Kelly A. Hadsell

#### Editor, Science and Medical News

Suzanne L. Rose

#### Assistant Editor

Elizabeth S. McKenna

#### Science Writer

Michele M. Hartsough

#### Editorial Associate

Jen Zimmerman

#### Associate Director, Production

Charlene Squibb

#### Senior Production Project Editor

Julie Ehlers

#### Director, Electronic Publishing

Robert Spanier

#### Electronic Publishing Staff

Mary Beth Cunney

John C. Ho

Diane M. Marinelli

Chris D. Wozniak

#### Associate Director,

#### Sales and Marketing

Nicola L. Hill

#### Sales and Marketing Staff

Karola Rac

### SCOPE

*Cancer Discovery* publishes high-impact, peer-reviewed articles describing major advances in research and clinical trials. The journal publishes Review Articles, Perspectives and Commentaries, News, and Research Watch summaries of important journal articles. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies.

*Cancer Discovery* is abstracted and/or indexed in *Web of Science*, *MEDLINE*, *Scopus*, *BIOSIS Previews*, and *Chemical Abstracts*.

### SUBMISSION OF MANUSCRIPTS

Online submission of manuscripts is welcomed at <http://cd.msubmit.net>. Before submitting a manuscript, please read the Instructions for Authors, which is available from the journal's home page at <http://cancerdiscovery.aacrjournals.org>.

### PUBLICATION CHARGES

Beginning with manuscripts submitted January 1, 2015 or after, articles will be published with the understanding that the author(s) will pay both a publication fee of \$2,500, plus a color figure handling fee of \$250 per figure.

### SUBSCRIPTION INFORMATION

Nonmember individual print with online subscription rate is \$525 (U.S.) or \$580 (outside the U.S.).

USA and Rest of World (excluding Japan)

Publications Sales & Marketing,  
American Association for Cancer  
Research, 615 Chestnut Street,  
Philadelphia, PA 19106; phone 1-855-  
744-4667; e-mail [pubsales@aacr.org](mailto:pubsales@aacr.org).

Japan

e-support@maruzen.co.jp; journal@  
kinokuniya.co.jp; usaco@usaco.co.jp.

### Site Licenses

Institutions wanting information about AACR Site Licenses (access open to multiple buildings and locations) and requests for quotes please contact [pubsales@aacr.org](mailto:pubsales@aacr.org).

### AACR Members

Subscription options are print with online access or online access only. Contact [membership@aacr.org](mailto:membership@aacr.org) or see <http://www.aacr.org> and go to the membership page for further information.

### Single Issue Sales

Subject to their availability, price for single or back issues is \$60 (U.S.) or \$65 (outside the U.S.) and must be prepaid. Contact [pubsales@aacr.org](mailto:pubsales@aacr.org).

### Claims

One-time claims for missing issues made within 120 days of the issue's publication, and subject to their availability, will be honored. No credits or refunds will be given if an issue is "out of print" at the time of claim.

### AACR Members

[membership@aacr.org](mailto:membership@aacr.org)

### Institutions and Nonmembers

[pubsales@aacr.org](mailto:pubsales@aacr.org).

### ADVERTISING INFORMATION

Inquiries about advertising should be directed to: Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, NY, NY, 10016; Phone: 212-904-0374; e-mail: [Mperlowitz@pminy.com](mailto:Mperlowitz@pminy.com).

### COPYRIGHT AND PERMISSIONS

Material printed in *Cancer Discovery* is covered and protected by copyright. Authors who wish to publish articles and other material in AACR journals must formally transfer copyright to the AACR. All authors must sign the copyright transfer form before AACR can proceed with publication.

To read the complete version of AACR's Copyright and Permissions Policy please visit <http://www.aacrjournals.org/site/InstrAuthors/ifora.xhtml#copyrightpermissions>

## IN THE SPOTLIGHT

# The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

Yanping Xiao and Gordon J. Freeman

**Summary:** The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in MSI colorectal cancer distinguishes MSI from microsatellite stable colorectal cancer and creates an immunosuppressive microenvironment that may help MSI tumors evade immune destruction by the infiltrating immune cells. Though colorectal cancer does not have a good response rate to PD-1 pathway immunotherapy, these results suggest that the MSI subset of colorectal cancer is a particularly good candidate for checkpoint immunotherapy. *Cancer Discov*; 5(1): 16-8. ©2015 AACR.

See related article by Llosa et al., p. 43 (3).

Microsatellite instable (MSI) colorectal cancer comprises approximately 15% of sporadic colorectal cancer and most familial colorectal cancer, whereas microsatellite stable (MSS) colorectal cancer comprises the remainder (1). MSI is typically diagnosed by the variable length of DNA microsatellites (mononucleotide and dinucleotide repeats; ref. 1). This variation is a consequence of epigenetic silencing or mutation of DNA mismatch repair genes (1, 2). Cells with abnormal mismatch repair function accumulate DNA replication errors, and novel microsatellite lengths are created. Impaired DNA mismatch repair facilitates insertions or deletions that can be frame-shift mutations as well as single-base mismatches that can be point mutations in coding regions. MSI allows mutations to be accumulated at many times the normal rate and facilitates MSI neoplastic progression (ref. 1; Fig. 1A).

The high mutational load in MSI tumors also creates many tumor-specific neoantigens, typically 10 to 50 times those of MSS tumors (3). Some of these neoantigens will be processed, presented on MHC, and recognized as foreign by T cells (Fig. 1A). In particular, frame-shifted proteins should be a rich source of neoantigens. This high neoantigen burden might be one explanation for the high level of tumor-infiltrating lymphocytes (TIL) and lymphocytic reaction in MSI tumors observed in many previous studies (1). MSI tumors have a better prognosis than MSS (2), and the higher level of neoantigens in MSI may contribute to better survival via more robust immunoediting of MSI (4).

In this issue of *Cancer Discovery*, Llosa and colleagues (3) analyzed primary sporadic colorectal cancer from patients

free of prior chemotherapy and found that a subset of primary sporadic colorectal cancer displayed high infiltration of activated CD8<sup>+</sup> cytotoxic T lymphocytes (CTL) as well as activated Th1 cells with IFN $\gamma$  production and the Th1 transcription factor T-bet. Th17 or Th2 populations were not expanded. They determined that nearly all of the tumors of this subset were MSI colorectal cancer.

Despite a robust Th1/CTL microenvironment, MSI tumors are not naturally eradicated, though some incipient MSI tumors may be eradicated and never seen as colorectal cancer. Llosa and colleagues determined the expression of immune checkpoint molecules by immunohistochemistry; laser capture microdissection of TILs, stroma, and the invasive front combined with quantitative RT-PCR; and multiparameter flow cytometry of fresh tumors (3). They show that compared with MSS tumors, MSI tumors highly upregulate expression of multiple immune checkpoints, including programmed death-1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in TILs, stroma, and invasive front compartments; PD-1 ligand 1 (PD-L1) in TILs and stroma compartments; lymphocyte activation gene 3 (LAG-3) in TILs and invasive front compartments; and indolamine 2,3-dioxygenase (IDO) in the TIL compartment (ref. 3; Fig. 1B).

PD-1 is upregulated after T-cell activation, but declines when antigen is cleared. If antigen is not cleared, as in chronic infection or cancer, PD-1 expression remains elevated and T cells can enter a state of decreased effector function and proliferative capacity, termed exhaustion. PD-1 has two ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273). Engagement of PD-1 by PD-L1 or PD-L2 results in inhibition of T-cell immune functions, as shown by decreased production of cytokines such as IFN $\gamma$  and IL2, decreased expression of cell survival proteins, altered motility and duration of interactions with dendritic cells (DC) and target cells, and altered metabolic activity. CTLA-4 is a potent inhibitory molecule that exerts its function via binding to CD80 and CD86, keeping them from delivering positive signals through CD28. LAG-3 is a CD4 homolog that binds MHC class II

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

**Corresponding Author:** Gordon J. Freeman, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-4585; Fax: 617-632-5167; E-mail: Gordon.Freeman@dfci.harvard.edu

doi: 10.1158/2159-8290.CD-14-1397

©2015 American Association for Cancer Research.




**Figure 1.** Immune microenvironment of MSI colorectal cancer. **A**, deficits in DNA mismatch repair genes cause defective DNA mismatch repair, resulting in high levels of gene mutations manifested as MSI, which facilitate progression into an MSI colorectal cancer. Mutation-generated neoantigens are processed and presented on antigen-presenting cells (APC) and stimulate T-cell activation, leading to an active Th1/CTL microenvironment; however, **(B)** upregulation of expression of checkpoint molecules such as PD-1, CTLA-4, and LAG-3 on T cells, PD-L1 on myeloid cells, and IDO expression in myeloid cells. APCs, and tumor cells delivers inhibitory signals to suppress T-cell activation, resulting in an immunosuppressive microenvironment. Green indicates activating and red inhibitory signals.

with a higher affinity than CD4. LAG-3 is important in controlling CD8<sup>+</sup> T-cell activity within target organs. LAG-3 is also required for maximal regulatory T-cell function and can inhibit DC function by engaging MHC II on DC. IDO is an enzyme that catalyzes the degradation of the essential amino acid tryptophan to kynurenine. Production and secretion of IDO are induced by IFN $\gamma$  and IL10. In the tumor microenvironment, IDO is produced by tumor cells, antigen-presenting cells (APC), tumor-associated myeloid-derived suppressor cells (MDSC), and tumor-associated macrophages (TAM) in response to these inflammatory signals. High levels of IDO reduce tryptophan levels and create kynurenine, both of which contribute to suppression of T-cell activity and are a potential mechanism for immune tolerance to tumor antigens (5).

In melanoma and many tumor types, the interface between the wave of infiltrating lymphocytes and the tumor is characterized by PD-L1 expression on the tumor cells (6). This is believed to be a consequence of T-cell recognition of the tumor leading to IFN $\gamma$  expression by the T cells that in turn stimulates PD-L1 expression on the tumor cells. This IFN $\gamma$  and PD-L1 expression constitutes a feedback loop, inhibiting the T-cell antitumor response via engagement of PD-1 by PD-L1. In contrast, in MSI colorectal cancer the interface between tumor and T cells was characterized by little expression of PD-L1 on the tumor cells despite IFN $\gamma$  expression

by the T cells. Instead, the T-cell infiltrate was interlaced with an abundant PD-L1-positive myeloid cell population (3). Presumably, these PD-L1-positive myeloid cells serve to inhibit the T-cell response. These PD-L1-positive myeloid cells were characterized as CD11b<sup>+</sup>HLA-DR<sup>lo</sup>CD15<sup>+</sup>CD14<sup>+</sup>CD33<sup>+</sup>, which some investigators would call monocytic MDSC (7); however, there is not general agreement on human MDSC markers, and Llosa and colleagues did not pursue this point. They also explored the lack of PD-L1 expression on the MSI tumor cells and found that in response to IFN $\gamma$ , both MSI and MSS colorectal cancer cell lines modestly upregulated PD-L1 and HLA-DR in comparison with the robust upregulation on melanoma and other cancer cell lines (3). They speculated that this might be a consequence of impaired STAT1 signaling, but changes in IFN receptor might also be involved (3).

One mystery is why the high load of neoantigens does not lead to immune eradication of MSI colorectal cancer. MSI tumors most often arise on the right side of the body in the proximal colon, and recent work has shown that the gut microbiota contributes to the development of colorectal cancer. The abundance of *Fusobacterium* species, particularly *F. nucleatum*, in tumor tissue has been shown to be associated with MSI colorectal cancer (8). *Fusobacterium* proteins can selectively recruit tumor-infiltrating myeloid cells and inhibit T-cell proliferation (9). *Fusobacterium* may facilitate upregulation of checkpoint ligands such as PD-L1 in these recruited

myeloid cells. We would speculate that *Fusobacterium* might be critically involved in suppressing the immune response at the time when MSI begins to generate a high burden of neoantigens that should facilitate immune eradication. Once the T-cell population fails to eliminate the tumor, it lapses into a chronic response with high expression of exhaustion markers and susceptibility to immunoinhibitory signals.

Anti-PD-1 and anti-PD-L1 antibodies have demonstrated significantly durable efficacy in patients with melanoma, renal cancer, and non-small cell lung cancer (3). However, colorectal cancer appeared to be a poor responder to antibody blockade of PD-1 or PD-L1 in clinical trials (3). Because most MSI colorectal cancers typically present with lower-stage disease than MSS colorectal cancers, the MSI subtype represents only 5% to 6% of the stage IV colorectal cancer population (10), and likely there were few MSI patients in PD-1 and PD-L1 clinical trials, with 18 and 19 patients with advanced colorectal cancer, respectively.

All of the five checkpoint molecules upregulated in MSI tumors are currently being targeted clinically with inhibitors (3). The FDA approved a CTLA-4 monoclonal antibody (mAb; ipilimumab) in 2010 and a PD-1 mAb (pembrolizumab) in 2014 for melanoma treatment, and multiple other pathway agents are in clinical trials and approaching approval. Multiple LAG-3 mAbs and small-molecule IDO pathway inhibitors are in development or clinical trials. On the basis of Llosa and colleagues' findings of high expression of PD-1 and PD-L1 in MSI colorectal cancer, two clinical trials have been initiated to test PD-1 blockade in patients with MSI colorectal cancer (3). Combinations with IDO, LAG-3, CTLA-4, and other checkpoints will likely follow.

This still leaves a great need for effective immunotherapies in the remaining 95% of stage IV colorectal cancer. As the checkpoint blockade molecules were discovered by their effects on immune tolerance, this suggests we need to deepen our understanding of the specialized mechanisms of gut immune tolerance to identify additional targets for colorectal cancer immunotherapy.

### Disclosure of Potential Conflicts of Interest

Y. Xiao is an inventor on a patent application for PD-L2 interaction with repulsive guidance molecule b which has been licensed to Novartis. G.J. Freeman is a consultant/advisory board member for

Novartis and has patents and receives patent royalties on the PD-1 pathway from Bristol-Myers Squibb, Merck, Roche, EMD Serono, Amplimmune/AstraZeneca, Boehringer-Mannheim, and Novartis.

### Grant Support

This work was supported by NIH grants P01AI056299, U54CA163125, P50CA101942, and HHSN272201100018C (to G.J. Freeman).

Published online January 12, 2015.

### REFERENCES

1. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. *Cancer* 2001;91:2417-22.
2. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. *Gut* 2009;58:90-6.
3. Llosa NJ, Cruise M, Tam A, Wick EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov* 2015;5:43-51.
4. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature* 2014;515:577-81.
5. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. *Cancer Immunol Immunother* 2014;63:721-35.
6. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med* 2012;4:127ra37.
7. Rudolph BM, Loquai C, Gerwe A, Bacher N, Steinbrink K, Grabbe S, et al. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. *Exp Dermatol* 2014;23:202-4.
8. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, et al. *Fusobacterium* in colonic flora and molecular features of colorectal carcinoma. *Cancer Res* 2014;74:1311-8.
9. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 2013;14:207-15.
10. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. *J Natl Cancer Inst* 2013;105:1151-6.

LC COPYRIGHT  
0 045 505 794 2

# AACR CANCER PROGRESS REPORT 2014


TRANSFORMING LIVES THROUGH RESEARCH

Get your FREE copy of the *AACR Cancer Progress Report 2014* by visiting [CancerProgressReport.org](http://CancerProgressReport.org), and learn about the many ways in which research is transforming lives. Some of the recent advances you will learn about include:

FROM AUG. 1, 2013, TO JULY 31, 2014, THE FDA HAS APPROVED:



**6 new** anticancer therapeutics.  
**5 new uses** for previously approved anticancer therapeutics.



**2 new uses** for imaging agents.



**1 new use** for a screening test.

RESEARCH IS TRANSFORMING LIVES BY ALLOWING US TO:



advance immunotherapeutic development;



develop new molecularly targeted therapeutics; and



overcome drug resistance.

**AACR**

American Association for Cancer Research

FINDING CURES TOGETHER<sup>SM</sup>

AACR.org  
#CancerProgress14